Authors: Minori Rosales, Thomas Schuetz, Anna Gifford, Nicole Gampp, Alberto Visintin, Rachael Duffy, Diana Albu, Patricia Gonzalez, Kelly Ocasio, Karin Herrera, Kris F. Sachsenmeier A copy of the ...
CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Compass Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both ...
CTX-8371 is a bispecific antibody that simultaneously targets the programmed death receptor (PD-1) and the programmed death receptor ligand (PD-L1) that are expressed on immune cells and cancer cells ...
BOSTON--(BUSINESS WIRE)--Compass Therapeutics, Inc. (OTC:CMPX), a clinical-stage, oncology focused biotechnology company developing proprietary immuno-modulatory and anti-angiogenic antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results